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DISTINGUISHING FEATURE of acute promyelocytic leukemia (APL) is the translocation between chromosomes 15 and 17, t(15;17)(q22-24;qll-21), present in the bone marrow (BM) cells of most patients with this disease.' Because this specific translocation is not found in other subtypes of the acute myeloid leukemias, it has become an important marker in the diagnosis of APL. However, difficulties are involved in providing definitive cytogenetic evidence for the presence or absence of t(15;17) cells in patients in clinical remission. Cytogenetic evaluations are dependent on finding an adequate number of metaphases of sufficient quality to identify the translocation; yet the quality of BM cultures from APL patients is frequently suboptimal as a consequence of the disease itself. A recent report' in which 11 APL patients were evaluated during remission found that the 15;17 translocation was not present in any of the patients during remission; however, 6 of these patients relapsed within 2.5 to 30 months after the sample was taken. The 15;17 translocation was found in the relapsed marrow of only 1 patient, whereas 2 of the patients could not be evaluated cytogenetically because of the lack of analyzable metaphases and 3 were found to have a normal chromosome complement. A potentially more efficient method of analyzing the chromosomal constitution of leukemia BM is the fluorescence in situ hybridization (FISH). Using either chromosome painting or region-specific DNA probes, reports have shown the utility of applying this technique to the studies of various leukem i a~.~" FISH is not dependent on cell quality for an accurate chromosomal evaluation and can be used in the chromosomal analysis of both interphase and metaphase ~ells.6.~ As a result, a greater number of BM cells may be scored for the presence or absence of the chromosome marker that provides a higher probability of identifying residual leukemia clones.
In this study, we used metaphase FISH in the chromosomal evaluation of 10 APL patients to determine the utility of FISH in detecting residual leukemic cells. All 10 patients were known from conventional cytogenetics to have the 15;17 translocation at presentation, and all were in clinical remission when first studied. Results of this study suggest that FlSH is more efficient than conventional cytogenetics in detecting residual malignant cells. Because the reverse transcription polymerase chain reaction (RT-PCR) assay has been shown to be an extremely sensitive method for de- tecting residual APL cells,"" a two-round nested RT-PCR assay was performed in 9 of the 10 APL patients studied by FISH to confirm the presence or absence of residual leukemic cells. Comparison of FISH and RT-PCR data shows that the two test results are in general agreement. From these studies, we conclude that FISH is potentially a useful method for detecting proliferating residual leukemic cells and for predicting relapse in APL patients.
MATERIALS AND METHODS

Patients and controls.
This study was a prospective study on 10 APL patients who received treatment at the University of Texas M.D. Anderson Cancer Center. All 10 patients were known from conventional cytogenetics to have the 15;17 translocation at presentation, and all were in clinical remission when first studied. These patients were studied by FISH, cytogenetics, and RT-PCR in all available follow-up samples with no prior knowledge of their clinical status. To avoid bias in scoring hybridization signals, several slides from APL patients and controls were coded and randomly mixed before each FISH procedure was performed. The control group consisted of 10 patients with other types of leukemia who did not have t(15;17) at presentation. One BM sample from each patient in the control group was analyzed by FISH. However, multiple BM samples from most APL patients were analyzed by FISH ( Table 1) . The duration of remission in our patient group ranged from 2 to 93 months when first studied (Table 1 ). All APL patients were initially treated with chemotherapy to achieve CR. Two patients (no. 9 * PCR results on the left are after a first round of 30 cycles using primer set PMLUl/RARDl; results shown on the right are after a second round of 30 cycles using primer set PMLUZIRARD3 or PMLU3RARD3 (see Materials and Methods).
10) were treated with amsacrine (AMSA) plus ara-C and the remaining 8 were treated with Idarubicin. Cell culture and in situ hybridization. BM cells were cultured overnight at 37°C in RPM1 medium supplemented with 20% fetal bovine serum without the addition of any mitogen. Colcemid (0.02 pg/mL) was added to the cultures 1 hour before harvest to arrest metaphases. Cells were made into slide preparations by the standard cytogenetic methods. For each hybridization, several slides from APL patients and controls were coded and randomly mixed before FISH was performed. The chromosome 17-specific DNA library probe, pBS-17 (gift of Dr Joe Gray, University of California, San Francisco) was used to detect cells with t(15;17). The probe DNA was biotinylated by the Bionick Labeling System (Bethesda Research Laboratories, Gaithersburg, MD) according to the manufacturer's instructions. Procedures for FISH, probe detection, and microscopy followed that described previously?.'' FISH analysis. Slides from patients and controls were coded and mixed before FISH analysis and all slides were read by two observers. Each observer analyzed the same 18 X 18 mm coverslip area and scored for the presence or absence of t(15;17) in each metaphase. The number of scored metaphases per slide varied and was determined by the culture quality; however, no more than 100 metaphases were scored in each slide. Because both observers scored the same area and their results were similar, an average was used as the final value for each slide.
Cytogenetics. Similar cell culture and slide preparation procedures were used for both cytogenetics and FISH. Cytogenetics was performed in the clinical cytogenetics laboratory that routinely analyzes 25 metaphases per BM sample for diagnostic purposes. FISH and cytogenetic results were compared only after the completion of this study.
Detection of the fusion transcript PML-RARa by RT-PCR. The breakpoint site of the fusion transcript, PML-RARa, was amplified by a two-round nested RT-PCR. RT-PCR was performed as previously described" with some modifications. In all PCR, reagents were added except the Taq polymerase (Promega Corp, Madison, WI), which heated to 75°C for 5 minutes, and then the PCR was started by the addition of Taq polymerase (2.5 U in 20 pL). Thirty cycles of PCR were performed with primer set PMLUURARDI. An aliquot of 2 pL was removed from the first-round PCR product and a secondround PCR was performed for 30 cycles with primer set PMLU2l RARD3 or PMLU3RARD3 for breakpoints occurring at site A or B of the PML gene, re~pectively.'~ Each cycle was performed at 94°C for 1 minute, 62°C for 1 minute, and 72°C for 2 minutes. The quality of the RNA samples was monitored by ethidium bromide staining after agarose gel electrophoresis and coamplification of the P2-microglobulin cDNA with primer set MGU (5"TTAGCTGTGC-TAC-3'). In all PCR, two negative controls were included: PCR with an RNA sample without the t(15;17) translocation and a minus RNA control to monitor contamination of reagents. All PCR-negative samples were repeated at least once. A positive control using RNA isolated from the APL-derived NB4 cells was also included in all PCR assays.
Oligonucleotide primers used for the amplification of PML-RARa cDNA are as follows: PMLUl (5'-TGCTGGACATGCACGG-TCGCGCTACT-3') and MGD (5"TAACCACAACCATGCCT-TTTCCT-3'), PMLU2 (5'-GATGGCTTCGACGAGlTCAAG-3'), PMLU3 (5'-GTCATCAAGATGGAGTCTGAGG-3'), RARD3 (5'-GGTCACCrrGlTGATGATGCAG-3'), and RARDl (5"CATGC-CCACTTCAAAGCACT-3'). These primer sequences were derived from the PML and RARa cDNA sequences, as previously rep~rted.'~.''
RESULTS
The pBS-17 probe is known to hybridize specifically with two chromosome 17s in a normal diploid cell yielding two Afluorescent signals after the FISH procedure. However, when this probe is hybridized to a leukemic cell with t(15;17), three fluorescent signals are observed representing a normal chromosome 17, a deleted chromosome 17, and the part of chromosome 17 translocated to chromosome 15. respectively (Fig 1A and B) .
In control samples, no cell with the characteristic three signals shown in Fig 1 was observed. There were, therefore, no false-positives among this group of controls. Table 1 shows results of FISH and cytogenetic studies of the 10 APL patients studied. In 6 patients (no. 1 through 4, 6, and 7), no metaphase with t( 15;17) was detected by either FISH or conventional cytogenetics in any of the samples examined. These patients remain in remission at the present time (May 1994). In 4 patients (no. 5 and 8 through lo), low frequencies of cells with t(15; 17) were detected by FISH in at least one sample examined. However, no cell with t( 15; 17) was detected by conventional cytogenetics. Interestingly, all 4 patients relapsed within 1 year after a positive FISH test.
For the 4 patients who suffered relapse, the FISH evaluation had identified residual leukemic cells before relapse. Patient no. 5 had three BM specimens analyzed by FISH. The first sample, obtained just before the third course of chemotherapy, showed approximately 2% of the cells with three signals; however, no cell with three signals was observed in the sample obtained approximately 1 year later. Of special interest was the result obtained with the third sample. Three of nine cells (33%) were found to have three fluorescent signals. Hematologic data of a sample taken at the same time suggested a relapse, although it could not be confirmed with a cytogenetic analysis because of poor quality preparations. Cytogenetic confirmation of relapse was made 1 week later.
Patient no. 8 also had three samples analyzed by FISH. In the first specimen, obtained 2 months after the last chemotherapy course and 7 months after complete clinical remission (CR), 2.8% of the cells analyzed had three signals. This percentage had increased to 3.6% in the second BM sample l I that was received 2 months before her first relapse. In both samples, a cytogenetic analysis found no cell with t( 15;17), yet this patient relapsed 2 months after the second analysis.
The first BM specimen of patient no. 9 was obtained when the patient had been in CR for 6 months. FISH analysis of one slide found no cell with three signals. Two months later, this frequency had increased to 13%, although no cell with t( 15; 17) was observed from a cytogenetic analysis of the 8 metaphase cells. One month after the FISH analysis, the patient relapsed.
Patient no. I O was still undergoing chemotherapy but had been in remission for 5 months when the first FISH evaluation was made. Two of the 71 cells (2.8%) showed three signals with the chromosome-17 probe. Analysis of a sample received approximately 4 weeks later found no cell with three fluorescence signals; however, the third sample that was obtained 9 months after achieving CR showed 8.3% of the cells to have three fluorescent signals. A cytogenetic analysis made from a sample taken at the same time found no cell with t( 15; 17) in 25 metaphases. This patient relapsed 1 month later. Table I also shows results of the RT-PCR assay in 9 of the IO patients studied by FISH. In general, there is a good agreement between the two tests. For example, in patients no. 1 through 4 and 6, in whom FISH results were negative, RT-PCR results were also negative after both the first and second round of amplification. In patients no. 5 and 8 through IO, in which FISH was tested positive in at least one sample, PCR was also tested positive after the first or second round of amplification. In only a few samples did we not observe complete agreement between the two tests. For example, in one sample from patient no. 5 and in one sample from patient no. 9, FISH tests were negative and RT-PCR tests were also negative after the first round, but were positive after the second round. This difference is likely the result of different sensitivities between the two methods of detection.
DISCUSSION
Monitoring of residual disease in APL patients is important for effective treatment planning because CR is
achievable with current chemotherapeutic regimens and because patients who have achieved CR can either remain in long-term CR or may relapse a few months or years Therefore, a test that could be used to predict which patients are likely to relapse would be extremely valuable in patient management.
The specific genetic alteration found in the leukemic cells of APL patients, ie, the translocation between chromosomes 15 and 17, t(15;17), allows detection of leukemic cells by the conventional G-banding method. Although the cytogenetic method is useful in confirming the presence of the characteristic chromosomal translocation at disease presentation, the low frequencies of leukemic cells that are present in patients in CR are usually below the detection limit of this test, which is approximately 5%. Therefore, other tests with higher sensitivities are needed for monitoring patients in CR. This study explores the utility of the FISH test in detecting residual leukemic cells and in identifying APL patients at high risk of relapse. Results of FISH are then compared with those of conventional cytogenetics and RT-PCR.
The advantage of FISH over conventional cytogenetics in detecting residual t(15;17) cells is apparent from the results of this study. A larger number of metaphases may be evaluated by FISH for the presence or absence of the translocation for two major reasons: (1) because detection oft( 15; 17) cells by FISH is not limited by chromosome morphology, poorly spread metaphases that are difficult to analyze by cytogenetics can be analyzed by FISH; and (2) metaphases can be much more rapidly screened by counting fluorescent signals than by analyzing banding patterns. The increased number of metaphases that could be routinely screened by FISH increases the likelihood that a small percentage of leukemic cells can be detected. Early detection of these residual leukemic cells in CR patients may serve as a warning for potential relapse. Our data support this contention. For example, of the 10 APL patients that we observed prospectively at various times during CR, leukemic cells with t(15;17) were detectable in 4 patients by FISH. All 4 patients relapsed l to 14 months later. In contrast, the cytogenetic test did not detect residual leukemic cells in any sample examined before relapse. Therefore, these results suggest that FISH is potentially a more powerful tool than cytogenetics in detecting residual leukemic cells and in identifying patients at high risk of relapse. Results from this study merits further investigation into the utility of FISH in predicting relapse in a larger number of APL patients. Ideally, all patients should be studied at the same intervals after they achieved CR.
The presence or absence of residual APL cells as determined by FISH was also confirmed by a two-round nested RT-PCR assay, which detects the PML-RARa fusion transcript encoded from the breakpoint junctions of t(15;17). As shown in Table 1 , samples obtained from 9 of the 10 patients were tested and the presence of residual diseases in these samples is in general agreement with the results obtained by FISH. Disagreement was seen in only 2 of 16 samples. For example, in one sample from patient no. 5 and in one sample from patient no. 9, FISH tests were negative and RT-PCR tests were also negative after the first round, but were positive after the second round. Therefore, a two-round nested RT-PCR appears to be more sensitive than FISH. The sensitivity of FISH may be further improved by analysis of an increased number of metaphases, eg, several hundreds.
Although the time to relapse is difficult to determine after a sample is tested positive by FISH or RT-PCR, both of these assays appear useful in distinguishing patients at high or low risk of relapse. For example, in this study, patients no. 1 through 3, whose samples repeatedly showed negative results by FISH and PCR, could be considered at low risk for relapse, whereas patients no. 5 and 8 through 10, whose samples showed positive results by FISH or PCR, could be considered at high risk for relapse. This information may be useful for considerations on further therapeutic strategies to eliminate residual leukemic cells.
The FISH test, albeit less sensitive than the PCR assay, offers several advantages for studying minimal residual disease. For example, the FISH test used in this study detects residual cells that are actively dividing. Conceivably, proliferating t( 15;17) cells are more likely to contribute to relapse than nonproliferating leukemic cells. Because the PCR test detects the t(15;17) regardless of the proliferative status or the degree of cell maturation, PCR positivity in APL patients 1 to 3 months after treatment usually reflects the presence of matured cells rather than the presence of leukemic blasts." Therefore, PCR positivity in early remission has been shown to be not predictive of relapse and the prognostic value of the PCR test becomes apparent only later after treatment.".'8.'9 Furthermore, the FISH test provides a quantitative measure of leukemic burden. Quantitation is apparently difficult with either the PCR or Southern hybridization method.8~"~".2"-22
The detection of residual leukemic cells in CR patients has not been found to have a predictive value for relapse in other types of leukemias. For example, in chronic myelogenous leukemia, cells carrying the abnormal BCWABL fusion genes are frequently found by the PCR test in patients in long-term remission, and the presence of these cells at low frequencies does not predict relapse." Similarly, in acute myelogenous leukemia M2 subgroup, detection of cells carrying the abnormal AML1ETO fusion genes by the PCR test is also not predictive of relap~e.'~.'~ However, our results are consistent with those of previous reports in suggesting that, in APL, there appears to be a correlation between the presence of residual disease and potential risks for relapse.'0.2'.26 If further studies on a large number of APL patients confirm the predictive value of FISH, this test could be very valuable for routine monitoring of APL patients in CR.
